Skip to main content
Erschienen in: Journal of Echocardiography 1/2019

14.07.2018 | Original Investigation

Implications of detection of foramen ovale patent after cryptogenic ischemic stroke

verfasst von: Rita Marinheiro, Leonor Parreira, Pedro Amador, Isabel Silvestre, Carla Antunes, Rui Caria

Erschienen in: Journal of Echocardiography | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Therapeutic uncertainty is inherent in decisions in patients with patent foramen ovale (PFO) and cryptogenic stroke. We aimed to determine clinical implications of PFO identification in transesophageal echocardiography (TEE) after a cryptogenic ischemic stroke.

Methods

Consecutive TEE done between 2011 and 2015 in patients with previous cryptogenic stroke was evaluated. Clinical implications of PFO identification (closure and/or medical therapy) were retrieved from the medical records and discharge summaries. Adverse events related to therapy, stroke recurrence and death were analyzed during follow-up.

Results

Three-hundred one patients (mean age 59 ± 11 years; 61% male) underwent a TEE, of which 77 (26%) patients had a diagnosis of PFO. Patients with PFO were younger (56 ± 13 versus 60 ± 14, p = 0.03). Of those with PFO, 23 (30%) underwent percutaneous closure of PFO and these patients had more frequently complex or large PFO (p < 0.001 and p = 0.004, respectively). The remaining 54 (70%) were treated with medical therapy: 30 (39%) with antiplatelet therapy and 24 (31%) with oral anticoagulation. During follow-up (44 ± 17 months), only two patients had another stroke (both referred for PFO closure, while they were waiting for the procedure) and two patients, on whom PFO closure was not performed, died (not for cardiovascular causes).

Conclusion

PFO’s (size and complexity) and patients’ characteristics influenced clinical decision when PFO was detected on TEE. The risk for recurrent stroke was not increased in patients who did not undergo PFO closure; although two patients waiting for PFO closure had recurrent stroke, demonstrating its importance.
Literatur
1.
Zurück zum Zitat Calvet D, Mas JL. Closure of patent foramen ovale in cryptogenic stroke: a never ending story. Curr Opin Neurol. 2014;27:13–9.CrossRefPubMed Calvet D, Mas JL. Closure of patent foramen ovale in cryptogenic stroke: a never ending story. Curr Opin Neurol. 2014;27:13–9.CrossRefPubMed
2.
Zurück zum Zitat Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991–9.CrossRefPubMed Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991–9.CrossRefPubMed
3.
Zurück zum Zitat Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092–100.CrossRefPubMed Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092–100.CrossRefPubMed
4.
Zurück zum Zitat Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083–91.CrossRefPubMed Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083–91.CrossRefPubMed
5.
Zurück zum Zitat Rengifo-Moreno P, Palacios IF, Junpaparp P, et al. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2013;34:3342–52.CrossRefPubMed Rengifo-Moreno P, Palacios IF, Junpaparp P, et al. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2013;34:3342–52.CrossRefPubMed
6.
Zurück zum Zitat Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011–21.CrossRef Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011–21.CrossRef
7.
Zurück zum Zitat Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033–42.CrossRefPubMed Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033–42.CrossRefPubMed
8.
Zurück zum Zitat Ay H, Furie KL, Smith WS, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005;58(5):688–97.CrossRef Ay H, Furie KL, Smith WS, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005;58(5):688–97.CrossRef
10.
Zurück zum Zitat Vitarelli A, Mangieri E, Capotosto L, et al. Echocardiographic findings in simple and complex patent foramen ovale before and after transcatheter closure. Eur Heart J Cardiovasc Imaging. 2014;15(12):1377–85.CrossRefPubMed Vitarelli A, Mangieri E, Capotosto L, et al. Echocardiographic findings in simple and complex patent foramen ovale before and after transcatheter closure. Eur Heart J Cardiovasc Imaging. 2014;15(12):1377–85.CrossRefPubMed
11.
Zurück zum Zitat Pepi M, Evangelista A, Nihoyannopoulos P, et al. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism European Association of Echocardiography. Eur J Echocardiogr. 2010;11:461–76.CrossRefPubMed Pepi M, Evangelista A, Nihoyannopoulos P, et al. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism European Association of Echocardiography. Eur J Echocardiogr. 2010;11:461–76.CrossRefPubMed
12.
Zurück zum Zitat Kaatz S, Ahmad D, Spyropoulus C, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119–26.CrossRefPubMed Kaatz S, Ahmad D, Spyropoulus C, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119–26.CrossRefPubMed
13.
Zurück zum Zitat Saric M, Armour AC, Arnaout MS, et al. Guidelines for the use of echocardiography in the evaluation of a cardiac source of embolism. J Am Soc Echocardiogr. 2016;29(1):1–42.CrossRefPubMed Saric M, Armour AC, Arnaout MS, et al. Guidelines for the use of echocardiography in the evaluation of a cardiac source of embolism. J Am Soc Echocardiogr. 2016;29(1):1–42.CrossRefPubMed
14.
Zurück zum Zitat McGrath ER, Paikin JS, Motlagh B, et al. Transesophageal echocardiography in patients with cryptogenic ischemic stroke: a systematic review. Am Heart J. 2014;168:706–12.CrossRefPubMed McGrath ER, Paikin JS, Motlagh B, et al. Transesophageal echocardiography in patients with cryptogenic ischemic stroke: a systematic review. Am Heart J. 2014;168:706–12.CrossRefPubMed
15.
Zurück zum Zitat Handke M, Harloff A, Olschewski M, et al. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–8.CrossRefPubMed Handke M, Harloff A, Olschewski M, et al. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–8.CrossRefPubMed
16.
Zurück zum Zitat Rodrigues AC, Picard MH, Carbone A, et al. Importance of adequately performed valsalva maneuver to detect patent foramen ovale during transesophageal echocardiography. J Am Soc Echocardiogr. 2013;26:1337–43.CrossRefPubMed Rodrigues AC, Picard MH, Carbone A, et al. Importance of adequately performed valsalva maneuver to detect patent foramen ovale during transesophageal echocardiography. J Am Soc Echocardiogr. 2013;26:1337–43.CrossRefPubMed
17.
Zurück zum Zitat Buttignoni SC, Khorsand A, Mundigler G, et al. Agitated saline versus polygelatine for the echocardiographic assessment of patent foramen ovale. J Am Soc Echocardiogr. 2004;17:1059–65.CrossRefPubMed Buttignoni SC, Khorsand A, Mundigler G, et al. Agitated saline versus polygelatine for the echocardiographic assessment of patent foramen ovale. J Am Soc Echocardiogr. 2004;17:1059–65.CrossRefPubMed
18.
Zurück zum Zitat Gladstone D, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467–77.CrossRefPubMed Gladstone D, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467–77.CrossRefPubMed
19.
Zurück zum Zitat Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.CrossRefPubMed Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.CrossRefPubMed
Metadaten
Titel
Implications of detection of foramen ovale patent after cryptogenic ischemic stroke
verfasst von
Rita Marinheiro
Leonor Parreira
Pedro Amador
Isabel Silvestre
Carla Antunes
Rui Caria
Publikationsdatum
14.07.2018
Verlag
Springer Japan
Erschienen in
Journal of Echocardiography / Ausgabe 1/2019
Print ISSN: 1349-0222
Elektronische ISSN: 1880-344X
DOI
https://doi.org/10.1007/s12574-018-0388-2

Weitere Artikel der Ausgabe 1/2019

Journal of Echocardiography 1/2019 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.